Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

NCT00101647 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

197

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Dasatinib

Sponsor

Bristol-Myers Squibb